The Burden of Short-Acting β(2)-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program

INTRODUCTION: Preliminary results from the SABINA (SABA use IN Asthma) program showed lower overuse of short-acting β(2)-agonist (SABA) in Italy compared to other European countries. The aim of the present study was to ascertain whether SABINA’s results might have been affected by the Italian Nation...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Marco, Fabiano, D’Amato, Mariella, Lombardo, Francesco P., Micheletto, Claudio, Heiman, Franca, Pegoraro, Valeria, Boarino, Silvia, Manna, Giandomenico, Mastromauro, Francesca, Spennato, Simona, Papi, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280008/
https://www.ncbi.nlm.nih.gov/pubmed/34043208
http://dx.doi.org/10.1007/s12325-021-01772-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280008/
https://www.ncbi.nlm.nih.gov/pubmed/34043208
http://dx.doi.org/10.1007/s12325-021-01772-0

Ejemplares similares